Mallinckrodt tumbles after judge invalidates Inomax patents

The decision favors Praxair, which is developing a copycat version of the drug.

By Jacob Bell • Sept. 6, 2017

FDA delays review of Mylan and Biocon's Herceptin biosimilar

The companies had appeared set for a September approval after winning the backing of an FDA panel, but a final decision will now not come until December.

By Suzanne Elvidge • Sept. 6, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Novo Nordisk settles claims related to Victoza marketing

Without admitting fault, the Danish drugmaker will pay out $58 million to settle claims related to marketing of its best-selling drug. 

By Lisa LaMotta • Sept. 6, 2017

Industry Pulse: 10 charts on M&A, I/O and biosimilar threats

While Gilead's acquisition of Kite lifted the biotech sector, major dealmaking has been few and far between this year. Elsewhere, copycat biologics pose a growing threat to industry top-sellers. 

By Ned Pagliarulo • Sept. 1, 2017

Pfizer's Mylotarg gets a second shot at market

After being withdrawn in 2010, the cancer drug has been green lighted again with new dosing and a slightly different patient population. 

By Lisa LaMotta • Sept. 1, 2017

Aveo wins European approval for cancer drug, triggering milestone payment

Per a licensing deal with EUSA Pharma, Aveo receives $4 million for winning EU approval of Fotivda — money it will reinvest into drug development.

By Jacob Bell • Aug. 30, 2017

Shire launches newest ADHD med Mydayis

The drugmaker is currently weighing options for its neuroscience business, including a potential spin-off. 

By Suzanne Elvidge • Aug. 30, 2017

Location-based marketing drives real-time, real-world engagement with healthcare consumers

Americans today spend more than a quarter of their media time on mobile devices. To engage their target audiences in this new digital space, health and life sciences companies are turning to mobile advertising.

By Roni Robbins • Aug. 29, 2017

Boehringer gains approval for second Humira biosimilar in US

The decision gives the drugmaker its first copycat biologic and opens the door for new competition to AbbVie's blockbuster.

By Jacob Bell • Aug. 29, 2017

Novo's Victoza approved for CV benefit

The expanded label could help boost the type 2 diabetes drug, which has seen competition eat away at its market share. 

By Jacob Bell • Aug. 28, 2017

Bristol-Myers, Pfizer continue to build case for Eliquis

The pharmas have been conducting follow-up study and real-world analyses of the anticoagulant in a bid to boost market uptake.

By Ned Pagliarulo • Aug. 28, 2017

Adamas Parkinson's drug gains FDA approval

Gocovri is now the first drug OK'd for the treatment of dyskinesia in patients with the neurological disorder.

By Jacob Bell • Aug. 25, 2017

Novartis taps online retail exec for new digital role

New positions are needed for pharma companies seeking to speed technology adoption and incorporate digital into patient and clinical trial engagement.

By Lisa LaMotta • Aug. 24, 2017

In cost debate, Amgen stands by Repatha's value

New findings from an Amgen-backed study, while more supportive of the drug's value than other analyses, underscore the challenges posed by its hefty price tag.

By Ned Pagliarulo • Aug. 23, 2017

Alexion snags EU yes for new Soliris indication

The European Commission extended its approval of Soliris, allowing Alexion to sell the drug for another rare condition.

By Suzanne Elvidge • Aug. 23, 2017

ALK readies Odactra launch after Merck exit

The Danish drugmaker is ready to launch its house dust mite treatment after its big pharma partner pulled out of the collaboration in 2016.

By Lisa LaMotta • Aug. 22, 2017

PCSK9 inhibitors still too pricey, study finds

An analysis published in JAMA found list prices for the cholesterol-lowering drugs would need to be reduced to meet cost-effectiveness thresholds. 

By Ned Pagliarulo • Aug. 22, 2017

Cardiome shaken by FDA no-go on heart drug refiling

The Canadian drugmaker's stock fell by almost a quarter after disclosing the data package for Brinavess wasn't sufficient for a resubmitted New Drug Application.

By Jacob Bell • Aug. 22, 2017

Ironwood wins FDA approval for combo gout drug

The biotech expects the oral therapy to further grow its gout franchise, established last year with the acquisition of U.S. rights to Zurampic from AstraZeneca. 

By Ned Pagliarulo • Aug. 21, 2017

Insys settles opioid lawsuit for $4.5M

The deal with the Illinois Attorney General is one of several settlements the opiod drugmaker has reached with states over the marketing of its fentanyl-based painkiller Subsys.

By Suzanne Elvidge • Aug. 21, 2017

Expanded label boosts AstraZeneca and Merck's Lynparza

Securing a broader indication for earlier treatment of ovarian cancer should help Lynparza fend off competition from rival PARP inhibitors.

By Ned Pagliarulo • Aug. 18, 2017

House Democrats to probe 'skyrocketing' prices for MS meds

Two top Democrats on the House Oversight Committee plan to investigate the pricing strategies of seven leading drugmakers in the space.

By Ned Pagliarulo • Aug. 17, 2017

J&J deal gives Cerecor much-needed cash infusion

Stung by a clinical setback late last year, Cerecor sold off rights to a depression drug candidate to help fund its pipeline development. 

By Suzanne Elvidge • Aug. 16, 2017

Alexion bolsters Soliris patent defense

Three new patent grants, including one for composition of matter, should help keep competition to the rare disease drug at bay. 

By Jacob Bell • Aug. 16, 2017

South Carolina slaps Purdue with opioid lawsuit

As the U.S. grapples with an opioid overdose epidemic, the Palmetto State joins the recent legal scrutiny of painkiller drug manufacturers.

By Suzanne Elvidge • Aug. 16, 2017